The NCT04396860 phase II/III trial compared standard-of-care therapy versus radiation therapy combined with ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1) in patients with newly diagnosed MGMT-unmethylated GBM [36]. Here, CTLA4 is linked to glioblastoma.